Lercanidipino Tecnigen

Lercanidipine, the active ingredient in Lercanidipino Tecnigen, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lercanidipino Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to manage high blood pressure by acting on the vascular smooth‑muscle calcium channels. - Hypertension: lowers systolic and diastolic pressure through vasodilation. - Essential hypertension: provides sustained blood‑pressure control in primary hypertension. - Isolated systolic hypertension: reduces elevated systolic readings in older adults.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, typically resolves with continued use. - Peripheral edema: swelling of ankles or feet, especially in the lower limbs. - Dizziness: sensation of light‑headedness, usually related to blood‑pressure changes.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue or throat that may compromise airway.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Hepatic function assessment: use with caution in patients with liver impairment. - Elderly patients: start at lower doses and monitor for orthostatic effects. - Concomitant antihypertensives: avoid additive hypotensive reactions. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Grapefruit juice: can raise systemic exposure and risk of hypotension. - Rifampicin: induces metabolism, reducing therapeutic effect.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood‑pressure lowering effect. - Diuretics: may enhance volume depletion and orthostatic symptoms.